Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 5, 2008, Pages 1519-1525

  Kloos, Richard T ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; THYROGLOBULIN; THYROGLOBULIN ANTIBODY;

AGED; CANCER RECURRENCE; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FEMALE; HUMAN; PRIORITY JOURNAL; REVIEW; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY;

EID: 43249107437     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-2357     Document Type: Article

References (65)

1. BR Haugen F Pacini C Reiners M Schlumberger PW Ladenson SI Sherman DS Cooper KE Graham LE Braverman MC Skarulis TF Davies LJ DeGroot EL Mazzaferri GH Daniels DS Ross M Luster MH Samuels DV Becker Maxon HR III RR Cavalieri CA Spencer K McEllin BD Weintraub EC Ridgway A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer J Clin Endocrinol Metab 84 1999 3877 3885
2. DS Cooper GM Doherty BR Haugen RT Kloos SL Lee SJ Mandel EL Mazzaferri B McIver SI Sherman RM Tuttle Management guidelines for patients with thyroid nodules and differentiated thyroid cancer Thyroid 16 2006 109 141
3. AS Alzahrani G Mohamed A Al Shammary S Aldasouqi SS Abdal M Shoukri Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer J Endocrinol Invest 28 2005 540 546
4. RT Kloos EL Mazzaferri A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later J Clin Endocrinol Metab 90 2005 5047 5057
5. J Jonklaas NJ Sarlis D Litofsky KB Ain ST Bigos JD Brierley DS Cooper BR Haugen PW Ladenson J Magner J Robbins DS Ross M Skarulis HR Maxon SI Sherman Outcomes of patients with differentiated thyroid carcinoma following initial therapy Thyroid 16 2006 1229 1242
6. BH Lang SM Chow CY Lo SC Law KY Lam Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers Ann Surg 246 2007 114 121
7. EL Mazzaferri RT Kloos Current approaches to primary therapy for papillary and follicular thyroid cancer J Clin Endocrinol Metab 86 2001 1447 1463
8. CF Eustatia-Rutten EP Corssmit NR Biermasz AM Pereira JA Romijn JW Smit Survival and death causes in differentiated thyroid carcinoma J Clin Endocrinol Metab 91 2006 313 319
9. TP Links KM van Tol PL Jager JT Plukker DA Piers HM Boezen RP Dullaart EG de Vries WJ Sluiter Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis Endocr Relat Cancer 12 2005 273 280
10. RN Anderson E Arias The effect of revised populations on mortality statistics for the United States, 2000 Natl Vital Stat Rep 51 2003 1 24
11. 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma J Clin Endocrinol Metab 90 2004 1440 1445
12. FT Hall NJ Beasley SJ Eski IJ Witterick PG Walfish JL Freeman Predictive value of serum thyroglobulin after surgery for thyroid carcinoma Laryngoscope 113 2003 77 81
13. JD Lin MJ Huang BR Hsu TC Chao C Hsueh FH Liu MJ Liou HF Weng Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas J Surg Oncol 80 2002 45 51
14. G Ronga M Filesi G Ventroni AR Vestri A Signore Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma Eur J Nucl Med 26 1999 1448 1452
15. KA Heemstra YY Liu M Stokkel J Kievit E Corssmit AM Pereira JA Romijn JW Smit Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma Clin Endocrinol (Oxf) 66 2007 58 64
16. 131I ablation for papillary and follicular thyroid carcinoma Thyroid 7 1997 265 271
17. CS Grant ID Hay IR Gough EJ Bergstralh JR Goellner WM McConahey Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery 104 1988 954 962
18. SI Sherman J Gopal Thyroglobulin positive, RAI negative thyroid cancers: the role of conservative management J Clin Endocrinol Metab 83 1998 4199 4200
19. F Pacini F Lippi N Formica R Elisei S Anelli C Ceccarelli Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels J Nucl Med 28 1987 1888 1891
20. M Schlumberger M Tubiana F De Vathaire C Hill P Gardet JP Travagli P Fragu J Lumbroso B Caillou C Parmentier Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma J Clin Endocrinol Metab 63 1986 960 967
21. M Tubiana M Schlumberger P Rougier A Laplanche E Benhamou P Gardet B Caillou JP Travagli C Parmentier Long-term results and prognostic factors in patients with differentiated thyroid carcinoma Cancer 55 1985 794 804
22. A Bachelot AF Cailleux M Klain E Baudin M Ricard N Bellon B Caillou JP Travagli M Schlumberger Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma Thyroid 12 2002 707 711
23. BD Lewis ID Hay JW Charboneau B McIver CC Reading JR Goellner Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma AJR Am J Roentgenol 178 2002 699 704
24. JM Monchik G Donatini J Iannuccilli DE Dupuy Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma Ann Surg 244 2006 296 304
25. EA Mittendorf X Wang ND Perrier AM Francis BS Edeiken SE Shapiro JE Lee DB Evans Follow-up of patients with papillary thyroid cancer: in search of the optimal algorithm J Am Coll Surg 205 2007 239 247
26. EL Mazzaferri RT Kloos Is diagnostic iodine-131 scanning with recombinant human TSH (rhTSH) useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87 2002 1490 1498
27. F Pacini E Molinaro MG Castagna L Agate R Elisei C Ceccarelli F Lippi D Taddei L Grasso A Pinchera Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma J Clin Endocrinol Metab 88 2003 3668 3673
28. M Torlontano M Attard U Crocetti S Tumino R Bruno G Costante G D'Azzo D Meringolo E Ferretti R Sacco F Arturi S Filetti Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases J Clin Endocrinol Metab 89 2004 3402 3407
29. JM Stulak CS Grant DR Farley GB Thompson JA van Heerden ID Hay CC Reading JW Charboneau Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer Arch Surg 141 2006 489 494
30. AS Alzahrani H Raef A Sultan S Al Sobhi S Ingemansson M Ahmed A Al Mahfouz Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent/persistent papillary thyroid cancer J Endocrinol Invest 25 2002 526 531
31. HM Binyousef AS Alzahrani SS Al Sobhi SH Al MA Chaudhari HM Raef Preoperative neck ultrasonographic mapping for persistent/recurrent papillary thyroid cancer World J Surg 28 2004 1110 1114
32. A Davila-Cervantes R Gamino O Gonzalez MF Herrera Surgical treatment of recurrent differentiated thyroid carcinoma Eur J Surg Suppl 588 2003 14 17
33. CY Lim JS Yun J Lee KH Nam WY Chung CS Park Percutaneous ethanol injection therapy for locally recurrent papillary thyroid carcinoma Thyroid 17 2007 347 350
34. MC Hung HS Wu CH Kao WK Chen SP Changlai F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan Endocr Res 29 2003 169 175
35. M Dietlein K Scheidhauer E Voth P Theissen H Schicha Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer Eur J Nucl Med 24 1997 1342 1348
36. H Palmedo J Bucerius A Joe H Strunk N Hortling S Meyka R Roedel M Wolff E Wardelmann HJ Biersack U Jaeger Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management J Nucl Med 47 2006 616 624
37. MJ Reinhardt N Wiethoelter A Matthies AY Joe H Strunk U Jaeger HJ Biersack PET recognition of pulmonary metastases on PET/CT imaging: impact of attenuation-corrected and non-attenuation-corrected PET images Eur J Nucl Med Mol Imaging 33 2006 134 139
38. N Khan N Oriuchi T Higuchi H Zhang K Endo PET in the follow-up of differentiated thyroid cancer Br J Radiol 76 2003 690 695
39. VJ Lowe BP Mullan ID Hay B McIver JL Kasperbauer 18F-FDG PET of patients with Hurthle cell carcinoma J Nucl Med 44 2003 1402 1406
40. M Plotkin H Hautzel BJ Krause D Schmidt R Larisch FM Mottaghy AR Boemer H Herzog H Vosberg HW Muller-Gartner Implication of 2-18fluor-2-deoxyglucose positron emission tomography in the follow-up of Hurthle cell thyroid cancer Thyroid 12 2002 155 161
41. DA Pryma H Schoder M Gonen RJ Robbins SM Larson HW Yeung Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients J Nucl Med 47 2006 1260 1266
42. Z Nahas D Goldenberg C Fakhry M Ewertz M Zeiger PW Ladenson R Wahl RP Tufano The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma Laryngoscope 115 2005 237 243
43. F Giammarile Z Hafdi C Bournaud M Janier C Houzard C Desuzinges R Itti G Sassolas F Borson-Chazot Is [18F]2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake? Eur J Endocrinol 149 2003 293 300
44. JV Ruiz Franco-Baux I Borrego Dorado CP Gomez Rodriguez R Jr RJ Vazquez Albertino GE Navarro JR Astorga [F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan] Rev Esp Med Nucl 24 2005 5 13
45. A Iagaru R Masamed PA Singer PS Conti 2-Deoxy-2-[18F]fluoro-d-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer Mol Imaging Biol 8 2006 309 314
46. B Schluter KH Bohuslavizki W Beyer M Plotkin R Buchert M Clausen Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan J Nucl Med 42 2001 71 76
47. LA Zimmer B McCook C Meltzer M Fukui D Bascom C Snyderman DW Townsend JT Johnson Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer Otolaryngol Head Neck Surg 128 2003 178 184
48. M Zoller S Kohlfuerst I Igerc E Kresnik HJ Gallowitsch I Gomez P Lind Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging 34 2007 487 495
49. A Shammas B Degirmenci JM Mountz BM McCook B Branstetter BB Bencherif JM Joyce SE Carty HA Kuffner N Avril 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer J Nucl Med 48 2007 221 226
50. F Grunwald HJ Biersack FDG PET in thyroid cancer: thyroxine or not? J Nucl Med 41 2000 1996 1998
51. L Hooft OS Hoekstra W Deville P Lips GJ Teule M Boers MW van Tulder Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer J Clin Endocrinol Metab 86 2001 3779 3786
52. KM van Tol PL Jager DA Piers J Pruim EG de Vries RP Dullaart TP Links Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation Thyroid 12 2002 381 387
53. T Petrich AR Borner D Otto M Hofmann WH Knapp Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma Eur J Nucl Med Mol Imaging 29 2002 641 647
54. BB Chin P Patel C Cohade M Ewertz R Wahl P Ladenson Recombinant human thyrotropin stimulation of fluoro-d-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma J Clin Endocrinol Metab 89 2004 91 95
55. W Wang SM Larson RM Tuttle H Kalaigian K Kolbert M Sonenberg RJ Robbins Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine Thyroid 11 2001 1169 1175
56. U Feine R Lietzenmayer JP Hanke J Held H Wohrle W Muller-Schauenburg Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer J Nucl Med 37 1996 1468 1472
57. RM Tuttle R Leboeuf RJ Robbins R Qualey K Pentlow SM Larson CY Chan Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer J Nucl Med 47 2006 1587 1591
58. K Kulkarni DV Nostrand F Atkins M Aiken K Burman L Wartofsky The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer Thyroid 16 2006 1019 1023
59. H Hanscheid M Lassmann M Luster SR Thomas F Pacini C Ceccarelli PW Ladenson RL Wahl M Schlumberger M Ricard A Driedger RT Kloos SI Sherman BR Haugen V Carriere C Corone C Reiners Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal J Nucl Med 47 2006 648 654
60. W Wang SM Larson M Fazzari SK Tickoo K Kolbert G Sgouros H Yeung H Macapinlac J Rosai RJ Robbins Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer J Clin Endocrinol Metab 85 2000 1107 1113
61. RJ Robbins Q Wan RK Grewal R Reibke M Gonen HW Strauss RM Tuttle W Drucker SM Larson Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-d-glucose-positron emission tomography scanning J Clin Endocrinol Metab 91 2006 498 505
62. GC Hovens MP Stokkel J Kievit EP Corssmit AM Pereira JA Romijn JW Smit Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer J Clin Endocrinol Metab 92 2007 2610 2615
63. E Baudin CD Cao AF Cailleux S Leboulleux JP Travagli M Schlumberger Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients J Clin Endocrinol Metab 88 2003 1107 1111
64. D Van Nostrand J Neutze F Atkins Side effects of “rational dose” iodine-131 therapy for metastatic well-differentiated thyroid carcinoma J Nucl Med 27 1986 1519 1527
65. NC Hall RT Kloos PET imaging in differentiated thyroid cancer: where does it fit and how do we use it? Arq Bras Endocrinol Metabol 51 2007 793 805